Prophylaxis News and Research RSS Feed - Prophylaxis News and Research

People with lymphatic filariasis more likely to acquire HIV infection, study shows

People with lymphatic filariasis more likely to acquire HIV infection, study shows

People infected with a parasitic worm called Wuchereria bancrofti in areas where HIV is endemic may be more likely to acquire HIV than people who are not infected with the worm, according to a new study in southwest Tanzania, published in The Lancet. [More]
Early initiation of prophylaxis linked to lower rates of PE and DVT in patients with severe brain injuries

Early initiation of prophylaxis linked to lower rates of PE and DVT in patients with severe brain injuries

People who sustain a traumatic brain injury (TBI) are at high risk for developing deep vein thrombosis (DVT) and pulmonary embolism (PE). PE is a leading cause of death in these patients. [More]
Study provides new insights into real-world use of PrEP

Study provides new insights into real-world use of PrEP

Several studies presented today in an official press conference at the 21st International AIDS Conference in Durban provided new insights on the use of PrEP among a broad range of populations. [More]
JAIDS presents important information to prevent HIV epidemic among transgender individuals

JAIDS presents important information to prevent HIV epidemic among transgender individuals

Programs to reduce the high risk of HIV infection among transgender people are urgently needed—but efforts are hindered by a lack of accurate information on HIV prevalence, HIV incidence, and specific risk factors facing this key population. [More]
Study confirms efficacy of PrEP in reducing risk of HIV infection in men who have sex with men

Study confirms efficacy of PrEP in reducing risk of HIV infection in men who have sex with men

The last phase of ANRS IPERGAY has confirmed that "on-demand" pre-exposure prophylaxis (PrEP) is a highly effective method of reducing the risk of HIV infection in men who have sex with men and who report high-risk behavior. [More]
Maternal antiretroviral treatment eliminates HIV transmission to infants during breastfeeding

Maternal antiretroviral treatment eliminates HIV transmission to infants during breastfeeding

For HIV-infected mothers whose immune system is in good health, taking a three-drug antiretroviral regimen during breastfeeding essentially eliminates HIV transmission by breast milk to their infants, according to results from a large clinical trial conducted in sub-Saharan Africa and India. [More]
HOPE study seeks to understand safety of vaginal ring in protecting women against HIV

HOPE study seeks to understand safety of vaginal ring in protecting women against HIV

Women who took part in ASPIRE, a trial that found a vaginal ring containing an antiretroviral (ARV) drug called dapivirine was safe and helped protect against HIV, will soon be offered the opportunity to use the ring as part of a new study called HOPE. [More]
Studies shed new light on why young women in South Africa experience high rates of HIV infection

Studies shed new light on why young women in South Africa experience high rates of HIV infection

Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, shedding new light on why young women in South Africa have high rates of HIV infection. [More]
Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

A Houston Methodist research team received a nearly $4 million grant to test a transcutaneously refillable implant that administers pre-exposure prophylaxis drugs to subjects at risk of HIV-exposure. [More]
CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

Non-alcoholic steatohepatitis (NASH) is a serious hepatic condition that precedes hepatocellular carcinoma (HCC) and is currently untreatable. [More]
Study highlights ongoing global epidemic of HIV among gay men

Study highlights ongoing global epidemic of HIV among gay men

Gay, bisexual and other men who have sex with men continue to have disproportionately high burdens of HIV infection in countries of low, middle and high income around the world, a new study led by the Johns Hopkins Bloomberg School of Public Health suggests. [More]
Implementation science may help prevent mother-to-child HIV transmissions

Implementation science may help prevent mother-to-child HIV transmissions

An emerging field, known as implementation science, may help reduce the nearly 150,000 instances of mother-to-child HIV transmissions that occur annually around the world, mostly in developing countries. c [More]
New superbug test developed by TGen-NAU receives Australian patent

New superbug test developed by TGen-NAU receives Australian patent

Antibiotic-resistant infections should be easier to detect, and hospitals could become safer, thanks to a technology developed by the Translational Genomics Research Institute and Northern Arizona University, and protected under a patent issued by Australia. [More]
Topical delivery of AVR drug combination can provide complete protection against HIV

Topical delivery of AVR drug combination can provide complete protection against HIV

Researchers are edging ever closer to discovering the perfect combination of drugs and drug delivery system that will stop the sexual transmission of HIV. [More]
Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Controlling corneal blindness by 2030: an interview with Dr Pravin Vaddavalli

Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data. [More]
Coagadex now available for rare bleeding disorder patients in the UK

Coagadex now available for rare bleeding disorder patients in the UK

Bio Products Laboratory, Limited (BPL) today announced that Coagadex is now available for patients in the UK. [More]

NHS England takes too long to commission PrEP for HIV prevention

An effective treatment that can prevent HIV infection and reduce the human and financial costs of the preventable condition is taking too long to be commissioned and made available on the NHS, warns Deborah Gold, chief executive of the National Aids Trust, in an article published by The BMJ today. [More]
Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Simple, cheap chemical sensors may detect developing cancers in future

Simple, cheap chemical sensors may detect developing cancers in future

Many cancers could be successfully treated if the patient consulted the doctor sufficiently early. But how can a developing cancer be detected if it doesn't give rise to any symptoms? In the near future, suitably early diagnosis could be provided by simple and cheap chemical sensors - thanks to special recognizing polymer films developed at the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw. [More]
Advertisement
Advertisement